The future of clinical development is digital. From wearable sensors to AI-powered analysis, sponsors who embrace digital strategies will gain faster decisions, better data, and stronger regulatory confidence. Get a ste...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Logistical considerations in mRNA vaccine development
In this article, ICON’s Andreas Dreps and Martin Lachs discuss the logistical considerations in mRNA vaccine development.
©BioPharm International
-
Innovative laboratory testing methods for clinical monitoring of cell therapies using flow cytometry DDPCR and QPCR assays
In this article from International Biopharmaceutical Industry, Dr. Chad Galderisi, Vice President and Global Medical Director for ICON Specialty Laboratories explores how unique applications of PCR and flow cytometry can be used to provide critical and complementary data that is needed to bring new life-saving treatment options to patients.
Published by International Biopharmaceutical Industry Journal Volume 6 Issue 3
-
Challenges of expanding CAR-T Cell Therapy into solid tumors
Learn more about the challenges associated with developing CAR-T therapies for solid tumors in this article.
© Huber, B.; Joeckel, T. Challenges of Expanding CAR-T Cell Therapy into Solid Tumors. BioPharm International 2023, 36 (5), 22–23,27
-
Mainstreaming cell and gene therapy – Realizing its potential
This article looks at the Cell and gene therapies (CGT) landscape, the challenges biopharma companies face in running clinical trials and tips on how to surmount those obstacles.
-
CAR-T cell therapy in oncology
In this article,Brian HuberandTamie Joeckel, consider how cell and gene therapies could change the future of cancer treatments and bring new options to patients.
-
Cell and gene therapy specific market authorisation guidances
Brandon Fletcher, Principal, Cell and Gene Therapy, offers his insights on the key changes in regulatory guidance documents released by the US Food and Drug Agency.
-
Gene therapy – affordability, access and reimbursement
Brian Huber, Vice President, Drug Development Services, considers the affordability, access and reimbursement challenges within the gene therapy market.
-
Glycomics applications reinforce precision medicine
Nicole A. Cowan explores how glycomics is joining genomics and proteomics in the study of disease mechanisms and the development of novel therapeutics.
-
-
The changing face of cell and gene therapy: impacts on planning and executing trials
In this webinar review some of the factors investigational teams should now consider in the planning and execution of cell and gene therapy development programs.
